{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:42:36Z","timestamp":1790710956882,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019563","name":"Epilepsiforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019563","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The US Food and Drug Administration recently issued a warning against the use of the antiseizure medication lamotrigine in people at risk of cardiac rhythm and conduction abnormalities. This study assessed the risk of cardiac morbidity and mortality in new users of lamotrigine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a Danish population\u2010based cohort study, we followed cohort members aged \u226515\u2009years for the first 2\u2009years after they initiated lamotrigine therapy. The main outcomes were cardiac conduction disorders in people without pre\u2010existing cardiac morbidity and all\u2010cause mortality in people with pre\u2010existing cardiac morbidity. Cox proportional hazards models provided hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for comparison of the risk in current versus past users of lamotrigine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 91\u2009949 (36\u2009618 males [39.8%]) new users of lamotrigine (median age\u00a0=\u00a045.7\u2009years, interquartile range\u00a0=\u00a032.0\u201360.2\u2009years). Among users without pre\u2010existing cardiac disease (<jats:italic>n<\/jats:italic>\u00a0=\u00a086\u2009769), 194 (.23%) developed a cardiac conduction disorder. Comparison of the risk in current and past lamotrigine treatment periods yielded an adjusted HR of new onset cardiac conduction disorder of 1.03 (95% CI = .76\u20131.40). Among users with pre\u2010existing cardiac disease (<jats:italic>n<\/jats:italic>\u00a0=\u00a05180), 1150 (22.2%) died. Comparison of the risk in current and past lamotrigine treatment periods yielded an adjusted HR for all cause\u2010mortality of 1.05 (95% CI = .93\u20131.19).<\/jats:p><\/jats:sec><jats:sec><jats:title>Significance<\/jats:title><jats:p>In this large population\u2010based study, lamotrigine use was associated neither with a risk of cardiac conduction disorders in people without pre\u2010existing cardiac morbidity nor with all\u2010cause mortality in people with pre\u2010existing cardiac morbidity.<\/jats:p><\/jats:sec>","DOI":"10.1111\/epi.17339","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T10:49:21Z","timestamp":1655981361000},"page":"2371-2380","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Cardiac morbidity and mortality associated with the use of\u00a0lamotrigine"],"prefix":"10.1111","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9385-6435","authenticated-orcid":false,"given":"Jakob","family":"Christensen","sequence":"first","affiliation":[{"name":"National Center for Register\u2010Based Research, Department of Economics and Business Economics Aarhus University  Aarhus Denmark"},{"name":"Department of Neurology Aarhus University Hospital  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6282-2614","authenticated-orcid":false,"given":"Betina B.","family":"Trabjerg","sequence":"additional","affiliation":[{"name":"National Center for Register\u2010Based Research, Department of Economics and Business Economics Aarhus University  Aarhus Denmark"},{"name":"Center for Integrated Register\u2010Based Research Aarhus University  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9339-4170","authenticated-orcid":false,"given":"Julie Werenberg","family":"Dreier","sequence":"additional","affiliation":[{"name":"National Center for Register\u2010Based Research, Department of Economics and Business Economics Aarhus University  Aarhus Denmark"},{"name":"Center for Integrated Register\u2010Based Research Aarhus University  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60460-7"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00247-6"},{"key":"e_1_2_13_4_1","unstructured":"GlaxoSmithKline.LAMICTAL full prescribing information.https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Lamictal\/pdf\/LAMICTAL\u2010PI\u2010MG.PDF. Accessed 15 Jun 2022."},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0321"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.107.048504"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00132-0"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12475"},{"key":"e_1_2_13_9_1","volume-title":"Antiarrhythmic medications","author":"King GS","year":"2021"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03250.x"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03855.x"},{"issue":"3","key":"e_1_2_13_12_1","first-page":"798","article-title":"Data resource profile: the Danish National Prescription Registry","volume":"46","author":"Pottegard A","year":"2017","journal-title":"Int J Epidemiol"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S91125"},{"key":"e_1_2_13_14_1","volume-title":"NOMESCO classification of surgical procedures","year":"2012"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17037"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004094"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-014-9930-3"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/1403494811399958"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/1403494810395825"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/seiz.2000.0504"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16751"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22822"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.05.005"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16930"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2016.11.005"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7511.17.3.180"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03689.x"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17066"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1309"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2020.144847"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2022.106872"},{"key":"e_1_2_13_32_1","unstructured":"US Food and Drug Administration.Studies show increased risk of heart rhythm problems with seizure and mental health medicine lamotrigine (Lamictal) in patients with heart disease.2021.https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/studies\u2010show\u2010increased\u2010risk\u2010heart\u2010rhythm\u2010problems\u2010seizure\u2010and\u2010mental\u2010health\u2010medicine\u2010lamotrigine. Accessed 15 Jun 2022."}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.17339","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/epi.17339","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.17339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T09:30:55Z","timestamp":1692783055000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.17339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1111\/epi.17339"],"URL":"https:\/\/doi.org\/10.1111\/epi.17339","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,5]]},"assertion":[{"value":"2022-04-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}